Seven IPOs and one SPAC priced this past week, as more sizable issuers filed to go public in the US.Natural gas exporter Venture Global (VG) led the week’s listings, completing the largest US energy IPO in over a decade, though it raised less at a much...read more
Ascentage Pharma Group International, a commercial-stage Chinese biotech developing small molecule inhibitors for cancer, raised $126 million by offering 7.3 million ADSs at $17.25, below the as-converted last close of its shares on the Hong Kong Exchange...read more
Ascentage Pharma Group International, a commercial-stage Chinese biotech developing small molecule inhibitors for cancer, announced terms for its IPO on Tuesday.The Suzhou, China-based company plans to raise $149 million by offering 7.3 million ADSs at $20.34,...read more
Ascentage Pharma, a commercial-stage Chinese biotech developing small molecule inhibitors for cancer, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The company's shares are currently listed on the Hong Kong Stock...read more
US IPO Weekly Recap: Venture Global prices a pared-down IPO as more sizable deals join the pipeline
Seven IPOs and one SPAC priced this past week, as more sizable issuers filed to go public in the US.Natural gas exporter Venture Global (VG) led the week’s listings, completing the largest US energy IPO in over a decade, though it raised less at a much...read more
Hong Kong-listed biotech Ascentage Pharma prices US IPO at $17.25
Ascentage Pharma Group International, a commercial-stage Chinese biotech developing small molecule inhibitors for cancer, raised $126 million by offering 7.3 million ADSs at $17.25, below the as-converted last close of its shares on the Hong Kong Exchange...read more
Hong Kong-listed biotech Ascentage Pharma sets terms for $149 million US IPO
Ascentage Pharma Group International, a commercial-stage Chinese biotech developing small molecule inhibitors for cancer, announced terms for its IPO on Tuesday.The Suzhou, China-based company plans to raise $149 million by offering 7.3 million ADSs at $20.34,...read more
China-based cancer biotech Ascentage Pharma files for a $100 million US IPO
Ascentage Pharma, a commercial-stage Chinese biotech developing small molecule inhibitors for cancer, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The company's shares are currently listed on the Hong Kong Stock...read more